Development
Vera Therapeutics, Inc.
VERA
$19.25
-$1.39-6.73%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -102.77M | -107.35M | -102.04M | -89.06M | -73.46M |
| Total Depreciation and Amortization | -3.52M | -2.23M | -1.36M | -846.00K | -217.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.35M | 16.74M | 16.58M | 15.56M | 18.31M |
| Change in Net Operating Assets | 4.74M | 9.19M | 1.91M | 6.75M | 2.50M |
| Cash from Operations | -88.20M | -83.65M | -84.91M | -67.60M | -52.87M |
| Capital Expenditure | 0.00 | -38.00K | -44.00K | -62.00K | -62.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.55M | -63.18M | -18.82M | -70.49M | -88.93M |
| Cash from Investing | -44.55M | -63.22M | -18.86M | -70.55M | -88.99M |
| Total Debt Issued | 19.82M | 19.82M | 19.82M | 19.82M | 4.92M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 116.80M | 117.47M | 117.09M | 88.21M | 87.39M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.19M | -7.26M | -7.26M | -6.10M | -6.16M |
| Cash from Financing | 129.42M | 130.03M | 129.65M | 101.93M | 86.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.33M | -16.83M | 25.88M | -36.22M | -55.72M |